Literature DB >> 28590310

Medical Management of Endometriosis.

Saima Rafique1, Alan H Decherney.   

Abstract

Endometriosis is a chronic medical condition that affects around 6% to 10% of reproductive age women. Pelvic pain, dysmenorrhea, and infertility are the most common presenting symptoms. The disease is characterized by estrogen-dependent growth of the endometrial glands and stroma outside the endometrial cavity. The diagnosis requires a high degree of suspicion and can be only confirmed on histopathology. Treatment includes medical and surgical options. Both hormonal and nonhormonal medical options are available and are tried at first with a goal to control pain and stop the growth of the endometriotic lesions. Nonsteroidal anti-inflammatory drugs, oral contraceptive pills, gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors are some of the commonly used medications. With more research on the molecular and biochemical aspects of endometriosis, newer targets of therapy are being developed like selective progesterone receptor modulators, antiangiogenic factors and immunomodulators. In women who do not respond to medical therapy or have severe symptoms, surgical excision of the endometrial lesions and adhesions is often helpful and offers confirmatory diagnosis by histopathology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28590310      PMCID: PMC5794019          DOI: 10.1097/GRF.0000000000000292

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  57 in total

1.  Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis.

Authors:  L Fedele; S Bianchi; G Zanconato; A Portuese; R Raffaelli
Journal:  Fertil Steril       Date:  2001-03       Impact factor: 7.329

2.  Progesterone and transforming growth factor-beta coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis.

Authors:  K L Bruner; E Eisenberg; F Gorstein; K G Osteen
Journal:  Steroids       Date:  1999-09       Impact factor: 2.668

3.  The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.

Authors:  Francisco Delgado-Rosas; Raúl Gómez; Hortensia Ferrero; Francisco Gaytan; Juan Garcia-Velasco; Carlos Simón; Antonio Pellicer
Journal:  Reproduction       Date:  2011-08-23       Impact factor: 3.906

Review 4.  The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis.

Authors:  Paolo Vercellini; Paola Viganò; Edgardo Somigliana
Journal:  Curr Opin Obstet Gynecol       Date:  2005-08       Impact factor: 1.927

5.  Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study.

Authors:  Katharina Walch; Gertrud Unfried; Johannes Huber; Christine Kurz; Michael van Trotsenburg; Elisabeth Pernicka; René Wenzl
Journal:  Contraception       Date:  2008-09-25       Impact factor: 3.375

6.  Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib.

Authors:  Erbil Dogan; Uğur Saygili; Cemal Posaci; Burcin Tuna; Sezer Caliskan; Sabahattin Altunyurt; Bahadir Saatli
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

Review 7.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

Review 8.  Danazol for pelvic pain associated with endometriosis.

Authors:  V Selak; C Farquhar; A Prentice; A Singla
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome.

Authors:  Olof Stephansson; Helle Kieler; Fredrik Granath; Henrik Falconer
Journal:  Hum Reprod       Date:  2009-05-12       Impact factor: 6.918

10.  Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial.

Authors:  P R Koninckx; M Craessaerts; D Timmerman; F Cornillie; S Kennedy
Journal:  Hum Reprod       Date:  2008-06-12       Impact factor: 6.918

View more
  22 in total

1.  HORMONAL THERAPY IN WOMEN OF REPRODUCTIVE AGE WITH ENDOMETRIOSIS: AN UPDATE.

Authors:  A A Gheorghisan-Galateanu; M L Gheorghiu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

2.  An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma.

Authors:  Liying Xing; Ya-Nan Liu; Hongye Yao; Tingting Wang; Fuchen Xie; Shunbin Luo; Pingping Luo; Shengling Tang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

3.  Selective oestrogen receptor modulators (SERMs) for endometriosis.

Authors:  Maaike Ht van Hoesel; Ya Li Chen; Ai Zheng; Qi Wan; Selma M Mourad
Journal:  Cochrane Database Syst Rev       Date:  2021-05-11

4.  Long non-coding RNA DHRS4 antisense RNA 1 inhibits ectopic endometrial cell proliferation, migration, and invasion in endometriosis by regulating microRNA-139-5p expression.

Authors:  Xuan Cui; Shisan Zhou; Yongtao Lin
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  A case report: Rectal endometriosis mimicking rectal cancer.

Authors:  Li-Juan Zhao; Yuan-He Wang; Jing-Dong Zhang
Journal:  Int J Surg Case Rep       Date:  2018-10-24

6.  Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain.

Authors:  Salvatore Caruso; Marco Iraci; Stefano Cianci; Salvatore Giovanni Vitale; Valentina Fava; Antonio Cianci
Journal:  J Pain Res       Date:  2019-07-29       Impact factor: 3.133

Review 7.  Endometriosis and pain in the adolescent- striking early to limit suffering: A narrative review.

Authors:  Christine B Sieberg; Claire E Lunde; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2019-12-17       Impact factor: 8.989

8.  Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.

Authors:  Yutaka Osuga; Yoshifumi Seki; Masataka Tanimoto; Takeru Kusumoto; Kentarou Kudou; Naoki Terakawa
Journal:  BMC Womens Health       Date:  2021-06-21       Impact factor: 2.809

9.  Analysis of the relationship between COMT polymorphisms and endometriosis susceptibility.

Authors:  Jiajia Zhai; Lei Jiang; Aiping Wen; Jingde Jia; Lili Zhu; Bo Fan
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

Review 10.  Autonomic nervous system and inflammation interaction in endometriosis-associated pain.

Authors:  Yajing Wei; Yanchun Liang; Haishan Lin; Yujing Dai; Shuzhong Yao
Journal:  J Neuroinflammation       Date:  2020-03-07       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.